Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Radioactive drug may shrink aggressive prostate tumors before surgery

NCT ID NCT06798558

First seen Feb 23, 2026 · Last updated May 24, 2026 · Updated 18 times

Summary

This study tests whether a single dose of a radioactive drug (Lu-177-PSMA-617) given before surgery can shrink or eliminate high-risk prostate cancer. About 54 men with aggressive prostate cancer will receive the drug, then have their prostate removed. The goal is to see if the cancer is less advanced after treatment, potentially improving outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • John Theurer Cancer Center at Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact

  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

    NOT_YET_RECRUITING

    Washington D.C., District of Columbia, 20057, United States

    Contact

  • MedStar Washington Hospital Center

    NOT_YET_RECRUITING

    Washington D.C., District of Columbia, 20010, United States

    Contact

Conditions

Explore the condition pages connected to this study.